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An evaluation of gender and racial disparity in the
decision to treat surgically arterial disease
Daniel J. Amaranto, BA, Farah Abbas, MS, Seth Krantz, MD, William H. Pearce, MD, Edward Wang, PhD,
andMelina R. Kibbe, MD, Chicago, Ill
Objective: In 1994, our hospital reported a significant gender disparity in the treatment of peripheral artery disease (PAD).
The objective of this study was to determine if this gender-based treatment disparity still persists after 15 years.
Methods: A retrospective review of patients with PAD and carotid artery disease based on vascular laboratory studies was
performed from January 2006 to February 2008. PAD was identified by ankle-brachial index < 0.9 or abnormal
waveform. Treatable carotid artery disease was identified by symptomatic stenosis 60%-99% or asymptomatic stenosis
80%-99%. Patients with interventions before January 2006 were excluded. Demographics, risk factors, and interventions
were recorded. Univariate and multivariate analyses were performed to identify risk factors and independent predictors
of intervention.
Results: Of 2,313 peripheral artery studies, 592 patients with PAD and no prior intervention were identified. Sixty-five
(21.7%) of 299 men and 47 (16.0%) of 293 women underwent angioplasty, stenting, endarterectomy, or bypass grafting.
This difference was not significant (P  .077). However, by multivariate analysis of patients with critical limb ischemia,
Caucasian race was an independent predictor of intervention (P .010; odds ratio [OR] 3.363). Of 3,505 carotid duplex
studies, 253 patients with treatable carotid artery disease and no prior intervention were identified. Seventy-eight (52.7%)
of 148 men and 43 (41.0%) of 105 women underwent carotid endarterectomy (CEA) or stenting. This difference was not
significant (P  .065). However, by multivariate analysis, Caucasian race was identified as an independent predictor of
intervention (P  .015, OR 3.033). Insurance status was not a predictor of intervention in either the PAD (P  .70) or
carotid artery disease cohort (P  .99).
Conclusion: Our data reveal that gender was not an independent predictor of intervention for PAD or carotid artery
disease; however, Caucasian race independently predicted a greater likelihood of intervention in PAD patients with
critical limb ischemia and in the carotid artery disease cohort. This study demonstrates the importance of performance
assessments in uncovering unsuspected treatment disparities. ( J Vasc Surg 2009;50:1340-7.)Gender and race have a significant role in determin-
ing treatment options. Male and Caucasian patients have
been reported to receive more aggressive treatments in a
range of cardiovascular diseases.1-8 Studies have shown
that African Americans are less likely to be revascularized
for coronary and peripheral artery diseases (PAD).4-11
Non-Caucasians have higher rates of amputations than
Caucasians, which suggests that interventions on patients
with critical limb ischemia may be delayed or forgone
among non-Caucasians.4,7-11 Additionally, population stud-
ies have shown a greater prevalence of PAD among African
Americans versus Caucasians.12-14 African Americans, His-
panics, and women are less likely to receive adequate ca-
rotid artery evaluation following acute ischemic stroke, and
non-Caucasians are less likely to undergo carotid endarter-
ectomy (CEA) for stenosis.15-17 Carotid artery interven-
tions have been utilized more for Caucasians than non-
From the Division of Vascular Surgery, Northwestern University Feinberg
School of Medicine.
Competition of interest: none.
Reprint requests: Melina Kibbe, MD, Northwestern University, Division of
Vascular Surgery, 676 N. St. Clair St., Ste. 650, Chicago, IL 60611
(e-mail: mkibbe@nmh.org).
The editors and reviewers of this article have no relevant financial relation-
ships to disclose per the JVS policy that requires reviewers to decline
review of any manuscript for which they may have a competition of
interest.
0741-5214/$36.00
Published by Elsevier Inc. on behalf of the Society for Vascular Surgery.
doi:10.1016/j.jvs.2009.07.089
1340Caucasians, but it is unclear if the difference is more closely
related to the varying medical risks and benefits across
races, or if the problem is a public health issue.Many factors
contribute to these disparities, including comorbidities,
disease severity, and inherent tendencies toward atheroscle-
rosis that differ by gender and race.18 Inequalities may also
reflect that women and minorities have a misunderstanding
of their treatment options, lack of access to care, or mistrust
of the medical community when compared with men and
Caucasians.19-21 Given these findings, it is important to
uncover why gender and racial differences exist.
Determining reference points with performance re-
ports is a crucial method that can help identify unwanted
disparities and possibly reduce them.19,22,23 The existence
of disparities is well documented, and Ayanian asserts that
the current phase of treatment disparity research is focused
on finding and eliminating unfair practices.19 In 1993, the
National Institutes of Health Revitalization Act made it a
requirement to include women and minority subjects in
clinical trials, unless there was compelling evidence for their
exclusion.24 Although there was a subsequent increase in
the presence of women and minorities in research, both
groups remain underrepresented. In 1994, an evaluation of
gender disparity in the treatment of PAD was conducted at
our institution and revealed a significant difference in sur-
gical intervention rates betweenmen and women even after
controlling for disease severity and risk factors.25 Thus, the
aim of this study was to track any progress, or lack thereof,
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Our hypothesis was that a gender-based treatment disparity
in PAD no longer exists because of our increased awareness
of gender disparity. We also examined carotid artery disease
for the first time and included racial demographics in our
analysis. This study, as well as future evaluations of our
practice, may serve as reference points that identify reasons
for disparities.
METHODS
Patient cohort. This study was approved by the Insti-
tutional Review Board at Northwestern University. Adults
who underwent lower extremity arterial physiological stud-
ies or carotid artery duplex examinations in the vascular
laboratory at Northwestern Memorial Hospital (NMH)
between January 2006 and February 2008 comprised the
population for this study. Blood flow studies from the
laboratory were reviewed to identify patients with signifi-
cant PAD or carotid artery disease. PAD was determined
from laboratory records of the ankle-brachial index (ABI)
and Doppler waveform analysis. The PAD cohort included
all patients with an ABI less than 0.9 or an abnormal
waveform. All patients with a history of intervention for
PAD prior to 2006 were excluded from the analysis. Non-
invasive studies are performed on all patients scheduled for
lower extremity revascularization. Patients with studies
from outside hospitals were only included in the analysis if
they had vascular laboratory studies performed at our insti-
tution. Carotid artery disease was assessed from laboratory
studies of carotid artery stenosis determined by duplex
examination. Patients with carotid artery disease were iden-
tified by having greater than 60% stenosis with ipsilateral
symptoms (cerebrovascular accident [CVA], transient isch-
emic attack [TIA], or amaurosis fugax), or greater than 80%
stenosis without symptoms. All patients with a history of
intervention for carotid artery disease prior to 2006 were
excluded from the analysis.
Vascular laboratory studies. All vascular laboratory
studies were performed by a registered vascular technolo-
gist and reviewed by a certified staff vascular surgeon
(W.H.P.). The standard lower extremity noninvasive arte-
rial physiologic study or carotid artery duplex examination
was conducted and interpreted according to the Intersoci-
etal Commission for the Accreditation of Vascular Labora-
tory (ICAVL) guidelines in the NMH ICAVL-accredited
vascular laboratory. For measurements of the ABI, technol-
ogists used a Doppler probe to record the systolic and
diastolic pressures of the brachial, posterior tibial, and
dorsalis pedis arteries. Measurements were taken bilaterally
whenever possible. Contraindications to measuring pres-
sures were pain at the site of measurement or the absence of
the appropriate limb. ABI was calculated by dividing the
highest available lower extremity systolic pressure by the
highest brachial pressure. Studies were deemed abnormal if
the ABI was less than 0.9. Heavy calcification of blood
vessels sometimes rendered the Doppler measurement in-
valid. Therefore, in the case of an invalid ABI, abnormal
(non-triphasic) waveforms were considered to be indicativeof PAD. For cases confirmed by ABI, severity of PAD was
stratified into three classes: minimal disease (ABI, 0.5-0.9);
moderate disease (ABI, 0.3-0.49); and severe disease (ABI
 0.3). The presence of rest pain, tissue loss, or gangrene
anywhere on the lower extremities was defined as critical
limb ischemia. For the carotid artery disease cohort, duplex
examinations estimated the percentage of stenosis in the
lumen of the internal and common carotid arteries bilater-
ally. Stenosis greater than 60% or 80% of the internal
and/or common carotid arteries was the only determinant
of disease in symptomatic and asymptomatic patients, re-
spectively.
Interventions. Interventions for patients in the PAD
cohort included angioplasty, stenting, endarterectomy, or
bypass grafting. The interventions of patients in the carotid
artery disease cohort included endarterectomy or angio-
plasty and stenting.
Patient demographics. The medical records of pa-
tients with documented PAD or carotid artery disease were
retrospectively reviewed. There were 29 and 26 variables
recorded for patients with PAD and carotid artery disease,
respectively. These variables included demographics, co-
morbidities, severity of disease, and medications being
taken at the time of the most recent pre-operative assess-
ment in the Vascular Laboratory. Gender and race were
reported by patients during their hospital registration. All
patients who did not indicate Caucasian race were consid-
ered non-Caucasian.
Statistical analysis. Statistical analysis software (SAS
Inc, Cary, NC) was used to analyze the data. In order to
assess the decision to treat patients by surgical intervention,
the PAD and carotid artery disease cohorts were separated
into non-intervention and intervention groups for analysis.
Variables were compared using chi-squared analysis or the
Fig 1. Patients in the peripheral arterial disease cohort by gender
and intervention status.Fisher exact test. Determination of risk factors and inde-
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with univariate and multiple logistics regression analyses.
Differences between treatment groups were considered
significant for P  .05. Certain demographic and clinical
characteristics may have differed by gender or by race. Since
the statistical significance of clinical factors influenced by
gender or race may have been suppressed in univariate
analysis, a multivariate analysis was performed that con-
trolled for all variables included in univariate analysis.
RESULTS
Peripheral artery disease. Between January 2006 and
February 2008, 2,313 lower extremity arterial studies were
performed in the vascular laboratory (Fig 1). Of those
studies, 1,163 (50.3%) were identified as abnormal. After
excluding patients with prior intervention, our PAD cohort
for this study was 592 patients. In order to determine what
Table I. Demographics of patients with peripheral artery
Characteristics All patients (n  592)
Mean age (years  standard deviation) 70.1  12.0
 50 39 (6.6%)
50-65 137 (23.1%)
65-75 167 (28.2%)
75-85 188 (31.8%)
 80 61 (10.3%)
Male gender 299 (50.5%)
Insurance 581 (97.8%)
Caucasian race 336 (56.8%)
Non-Caucasian race 256 (43.2%)
PAD
ABI  0.9 441 (74.5%)
ABI  0.3 57 (9.6%)
ABI 0.3-0.49 108 (18.2%)
ABI 0.5-0.9 276 (46.6%)
Abnormal waveform only 151 (25.5%)
Type I diabetes mellitus 32 (5.4%)
Type II diabetes mellitus 231 (39.0%)
Hypertension 490 (82.8%)
Arrhythmia 121 (20.4%)
Coronary artery disease 300 (50.7%)
Myocardial infarction 93 (15.7%)
Congestive heart failure 104 (17.6%)
Coronary artery bypass graft 122 (20.1%)
Carotid artery disease 144 (24.3%)
Renal insufficiency 91 (15.4%)
Renal failure 63 (10.6%)
Current or past smoker 346 (58.4%)
Chronic obstructive pulmonary disease 64 (10.8%)
Hyperlipidemia 361 (61.0%)
Critical limb ischemia 195 (32.9%)
Preoperative clinic visit 338 (57.1%)
Medications
Aspirin 338 (57.1%)
Clopidogrel 149 (25.2%)
Warfarin 94 (15.9%)
Statin 360 (60.8%)
ACE inhibitor 256 (43.2%)
Beta blocker 331 (55.9%)
Other anti-hypertensive 260 (43.2%)
ABI, Ankle-brachial index; PAD, peripheral arterial disease.
Bolded items indicate statistical significance, ie P  .05.factors influenced the decision to operate, the populationwas divided into non-intervention and intervention groups.
Table I shows patient demographic data of the entire cohort as
well as by treatment group; it also shows the statistically
significant differences between non-intervention and inter-
vention groups as determined by chi-squared analysis. In
the PAD cohort, 480 (80.1%) of the patients received no
intervention, while 112 (18.9%) underwent intervention,
including angioplasty, stenting, endarterectomy, or bypass
grafting.
Of the entire PAD cohort, 50.5% were men and 49.5%
were women. Of those who did not receive an intervention,
48.8% were men, 51.2% were women. Of those who re-
ceived an intervention, 58.0% were men and 42.0% were
women (Table I). The difference between intervention
rates of men and women for PAD did not reach statistical
significance by univariate analysis (P .078; OR 1.454) or
multivariate analysis (P  .157; OR 1.412). However,
se
o intervention (n  480) Intervention (n  112) P
70.2  12.1 69.5  11.7 .611
30 (6.3%) 9 (8.0%)
110 (22.9%) 27 (24.1%)
140 (29.2%) 27 (24.1%)
148 (30.8%) 40 (35.7%)
52 (10.8%) 9 (8.0%)
234 (48.8%) 65 (58.0%) .077
470 (97.9%) 111 (99.1%) .696
263 (54.8%) 73 (65.2%) .046
217 (45.2%) 39 (34.8%) .046
353 (73.5%) 88 (78.6%) <.001
37 (7.7%) 20 (17.9%)
76 (15.8%) 32 (28.6%)
240 (50.0%) 36 (32.1%)
127 (26.5%) 24 (21.4%)
25 (5.2%) 7 (6.3%) .664
187 (39.0%) 44 (39.3%) .949
392 (81.7%) 98 (87.5%) .152
92 (19.2%) 29 (25.9%) .112
227 (47.3%) 73 (65.2%) <.001
75 (15.6%) 18 (16.1%) .907
80 (16.7%) 24 (21.4%) .233
89 (18.5%) 33 (29.5%) .010
112 (23.3%) 32 (28.6%) .245
73 (15.2%) 18 (16.1%) .820
47 (9.8%) 16 (14.3%) .165
266 (55.4%) 80 (71.4%) .002
47 (9.8%) 17 (15.2%) .098
286 (59.6%) 75 (67.0%) .066
136 (28.3%) 59 (52.7%) <.001
271 (56.5%) 67 (59.8%) .517
260 (54.2%) 78 (69.6%) .003
98 (20.4%) 51 (45.5%) <.001
73 (15.2%) 21 (18.8%) .356
280 (58.3%) 80 (71.4%) .011
203 (42.3%) 53 (47.3%) .333
259 (54.0%) 72 (64.3%) .048
203 (42.3%) 57 (50.9%) .099disea
Nrelatively fewer Caucasians were in the non-intervention
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group (73 [65.2%]; Fig 2). This difference was significant
by univariate analysis (P  .047; OR 1.544; Table II), but
not by multivariate analysis (P  .165; OR 1.432).
A sub-analysis was performed on patients with critical
limb ischemia. The results of the multivariate analysis
showed that Caucasian patients were far more likely to
receive revascularization than non-Caucasian patients (P
.010; OR 3.363). There was no difference between men
and women by the multivariate analysis of patients with
critical limb ischemia. Table II shows statistically significant
results from the univariate and multivariate analyses that
were performed on all demographic variables. By univariate
analysis, positive risk factors for intervention included cor-
onary artery disease (CAD) (P  .001; OR 2.086), prior
coronary artery bypass (P  .011; OR 1.835), history of
smoking (P .002; OR 2.011), critical limb ischemia (P
.001; OR 2.787), and usage of aspirin (P  .003; OR
1.941), clopidogrel (P  .001; OR 3.259), statins (P 
.011; OR 1.786), and beta-blockers (P .048; OR 1.536).
The intervention group was notable for a greater propor-
tion of severe (ABI 0.3; 17.9% versus 7.7%; P .001;OR
2.603) and moderate disease (ABI 0.3-0.49; 28.6% versus
15.8%; P  .002; OR 2.126), but a smaller proportion of
minimal disease (ABI 0.5-0.9; P  .001; OR 0.474).
Multivariate analysis revealed CAD (P .020; OR 1.954),
history of smoking (P  .007; OR 2.036), hyperlipidemia
(P  .034; OR 1.719), critical limb ischemia (P  .001;
OR 3.910), ABI  0.3 (P  .005; OR 3.052), and ABI
0.30-0.49 (P .001; OR 3.042) as independent predictors
of intervention among this cohort (Table II).
Carotid artery disease. Between January 2006 and
February 2008, 3,505 carotid artery duplex examinations
were performed in the vascular laboratory (Fig 3). Of those
studies, 2,498 (71.3%) were identified as abnormal (steno-
sis 1%-100%), among which 371 (14.9%) had significant
Fig 2. Percentage of Caucasian and Non-Caucasian patients with
PAD and carotid artery disease by intervention status. *Significant
by univariate analysis (P  .047; OR 1.544); **Significant by
multivariate analysis (P  .015; OR 3.033).disease (stenosis 60%-100%). The final population of thecarotid artery disease cohort was limited to 253 patients
who had treatable disease (stenosis  100%) and did not
have a history of a prior surgical intervention of their
carotid artery stenosis. In order to determine what factors
influenced the decision to operate, the population was
divided into non-intervention and intervention groups.
Table III shows the demographic data of the entire cohort
as well as by treatment group; it also shows significant
differences between the non-intervention and intervention
groups as determined by chi-squared analysis. In the ca-
rotid artery disease cohort, 132 (52.2%) of the patients
received no intervention, while 121 (47.8%) underwent
intervention by stenting or carotid endarterectomy (CEA).
Of the entire carotid artery disease cohort, 58.5% were
men and 41.5% were women. Of those who did not receive
an intervention, 53.0% were men and 47.0% were women.
Of those who received an intervention, 64.5% were men
and 35.5% were women (Table III). The difference be-
tween intervention rates of men and women for carotid
artery disease did not reach statistical significance by uni-
variate analysis (P  .066; OR 1.607) or multivariate
analysis (P  .168; OR 1.631). However, further analysis
revealed Caucasian race as an independent predictor of
intervention. Relatively fewer Caucasians were in the
non-intervention group (99 [75.0%]), while more were in
the intervention group (101 [83.5%]; Fig 2), and this
difference was significant by multivariate analysis (P 
.015; OR 3.033; Table IV). As shown in Fig 3, when
analyzed by symptoms, a more striking difference was ob-
served between the sexes. Of 199 asymptomatic patients,
56.8% were men and 43.2% were women. Of the asymp-
tomatic patients, 46.9% of men received an intervention,
whereas only 39.5% of the women did. This difference did
Table II. Logistics regression analysis of risk factors and
independent predictors for intervention on patients with
peripheral arterial disease
Characteristics Odds ratio P
Univariate analysis
Caucasian race 1.544 .047
Ankle-brachial index  0.3 2.603 .001
Ankle-brachial index 0.3-0.49 2.126 .002
Ankle-brachial index 0.5-0.9 0.474 .001
Coronary artery disease 2.086 .001
Coronary artery bypass graft 1.835 .011
Current or past smoker 2.011 .002
Critical limb ischemia 2.787 .001
Aspirin 1.941 .003
Clopidogrel 3.259 .001
Statin 1.786 .011
Beta blocker 1.536 .048
Multivariate analysis
Ankle-brachial index  0.3 3.052 .005
Ankle-brachial index 0.3-0.49 3.042 .001
Coronary artery disease 1.954 .020
Current or past smoker 2.036 .007
Hyperlipidemia 1.719 .034
Critical limb ischemia 3.910 .001not reach statistical significance (P  .299). Of 54 symp-
ipsilateral stroke, transient ischemic attack, or amaurosis fugax.
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Characteristics All (n  253) No intervention (n  132) Intervention (n  121) P
Mean age (years  standard deviation) 72.0  11.2 74.5  11.1 69.3  10.6 .001
 50 6 (2.4%) 2 (1.5%) 4 (3.3%)
50-65 59 (23.3%) 23 (17.4%) 36 (29.8%)
65-75 83 (32.8%) 42 (31.8%) 41 (33.9%)
75-85 67 (26.5%) 34 (25.8%) 33 (27.3%)
 80 38 (15.0%) 31 (23.5%) 7 (5.8%)
Male gender 148 (58.5%) 70 (53.0%) 78 (64.5%) .065
Caucasian race 200 (79.1%) 99 (75.0%) 101 (83.5%) .098
Non-Caucasian race 53 (20.9%) 33 (25.0%) 20 (16.5%) .098
Insurance 249 (98.4%) 130 (98.5%) 119 (98.3%) .999
Type I diabetes mellitus 14 (5.5%) 7 (5.3%) 7 (5.8%) .867
Type II diabetes mellitus 70 (27.7%) 40 (30.3%) 30 (24.8%) .328
Hypertension 205 (81.0%) 101 (76.5%) 104 (86.0%) .059
Arrhythmia 29 (11.5%) 14 (10.6%) 15 (12.4%) .655
Coronary artery disease 122 (48.2%) 68 (51.5%) 54 (44.6%) .274
Myocardial infarction 43 (17.0%) 26 (19.7%) 17 (14.0%) .232
Congestive heart failure 22 (8.7%) 12 (9.1%) 10 (8.3%) .816
Coronary artery bypass graft 68 (26.9%) 40 (30.3%) 28 (23.1%) .199
Renal insufficiency 24 (9.5%) 15 (11.4%) 9 (7.4%) .287
Renal failure 8 (3.2%) 7 (5.3%) 1 (0.8%) .068
Current or past smoker 103 (40.7%) 44 (33.3%) 59 (48.8%) .013
Chronic obstructive pulmonary disease 17 (6.7%) 5 (3.8%) 12 (9.9%) .052
Hyperlipidemia 181 (71.5%) 83 (62.9%) 98 (81.0%) .001
Symptomatic 54 (21.3%) 20 (15.2%) 34 (28.1%) .012
Preoperative clinic visit 187 (73.9%) 75 (56.8%) 112 (92.6%) <.001
Medications
Aspirin 167 (66.0%) 62 (47.0%) 105 (86.8%) <.001
Clopidogrel 72 (28.5%) 28 (21.2%) 44 (36.4%) .008
Warfarin 25 (9.9%) 16 (12.1%) 9 (7.4%) .212
Statin 166 (65.6%) 79 (59.8%) 87 (71.9%) .044
ACE inhibitor 78 (30.8%) 40 (30.3%) 38 (31.4%) .850
Beta blocker 123 (48.6%) 65 (49.2%) 58 (47.9%) .835Fig 3. Patients in the carotid artery disease cohort by symptoms, gender, and intervention status. Symptoms includeOther anti-hypertensive 104 (41.1%) 49 (37.1%) 55 (45.5%) .178
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Of the symptomatic patients, 71.4% of men received an
intervention, whereas only 47.4% of women did. This large
difference did not reach statistical significance (P  .080),
most likely due to the relatively small sample size of patients
with symptomatic disease (n  54).
Table IV shows statistically significant results from the
univariate andmultivariate analyses that were performed on
all demographic variables. By univariate analysis, positive
risk factors for intervention included history of smoking
(P  .013; OR 1.903), hyperlipidemia (P  .002; OR
2.515), prior amaurosis fugax (P  .028; OR 4.300),
symptomatic disease (P  .013; OR 2.188), preoperative
clinic visit (P .001; OR 9.458) and usage of aspirin (P
.001; OR 7.410), clopidogrel (P  .008; OR 6.988), and
statins (P  .045; OR 1.717). Multivariate analysis also
revealed age (P  .001; OR 0.937), history of smoking
(P  .038; OR 2.192), chronic obstructive pulmonary
disorder (P .032; OR 6.159), hyperlipidemia (P .001;
OR 4.227), prior TIA (P  .034; OR 0.289), and a
preoperative clinic visit (P  .001; OR 31.324) as inde-
pendent predictors of intervention among this cohort
(Table IV).
DISCUSSION
Clinical research in the field of surgery tends to focus on
the outcomes of successful operations. The decision to
treat, however, can be impeded by public health or socio-
economic factors. This project was conceived as an ac-
knowledgement of the efforts of past research that has
shown that treatment is not always equitable, and—more
importantly—that concerted efforts are required to ensure
and uphold its fairness.19,22 We hypothesized that, irre-
spective of medical history, women would be as likely as
men to receive surgical intervention for PAD and carotid
Table IV. Logistics regression analysis of risk factors and
independent predictors for intervention on patients with
carotid artery disease
Characteristics Odds ratio P
Univariate analysis
Current or past smoker 1.903 .013
Hyperlipidemia 2.515 .002
Prior amaurosis fugax 4.300 .028
Symptomatic disease 2.188 .013
Preoperative clinic visit 9.458 .001
Aspirin 7.410 .001
Clopidogrel 6.988 .008
Statin 1.717 .045
Multivariate analysis
Age 0.937 .001
Caucasian race 3.033 .015
Current or past smoker 2.192 .038
Chronic obstructive pulmonary disease 6.159 .032
Hyperlipidemia 4.227 .001
Prior transient ischemic attack 0.289 .034
Preoperative clinic visit 31.324 .001artery disease. Our research determined that gender wasnot a determinant of intervention, but surprisingly that
Caucasian race was an independent predictor of carotid
artery disease intervention. Caucasian race was also an
independent predictor of revascularization in patients with
critical limb ischemia. Thus, while we corrected the gender
disparity identified in 1994, we have now identified a
disparity between races.
There is no current evidence that suggests, given the
same indications, that intervention rates for PAD or carotid
artery disease should differ by gender or race. Many studies
have confirmed the negative consequences of delayed in-
tervention for PAD on African Americans.4,7,9-11 These
data on limb loss show that minority patients with PAD
should be considered as much as non-minorities for revas-
cularization. As for carotid artery disease, in 2008 the
Society for Vascular Surgery appointed a committee of
experts to create clinical guidelines for treatment of carotid
stenosis. The guidelines indicated that symptoms and de-
gree of stenosis are proper indicators of intervention, but
not gender or race.26 However, it should be noted that the
risk-benefit ratio for CEA has been reported to be different
between men and women; therefore, a treatment disparity
may be warranted.27
Disparities have been identified in the treatment of
PAD and carotid artery disease. Several studies have iden-
tified that minorities have higher amputation rates and are
less likely to undergo revascularization as opposed to am-
putation.4,7,8 These differences are most common among
African Americans with PAD. Feinglass et al found that
amputation disparities can exist in hospitals with varying
vascular surgery capacity and further suggested that socio-
economic inequality had a major influence on racial dispar-
ities.10,11 Kennedy et al found that non-Caucasians had
lower rates of initial CEA utilization and higher rates of
in-hospital death and stroke.16 Such findings underline
how disparities can skew complications toward minorities.
Jha et al aggregated Medicare data in 158 referral areas to
determine if racial disparities in intervention rates of nine
different procedures abated.22 Over 10 years the disparities
actually increased for most procedures, and in none of the
procedures was disparity eliminated. It is clear that treat-
ment disparities are prevalent and can lead to severe nega-
tive consequences in under-treated groups.
Many different etiologies account for treatment dispar-
ities. These include limited insurance coverage, patient
mistrust of healthcare providers and hospitals, patient mis-
understanding of disease severity and treatment options,
physician bias, and a lack of access to adequate health care
facilities and qualified personnel.4,7-11,19-21,27-34 The re-
sults of our gender analysis suggest that performance assess-
ments and increased self-awareness of treatment trends can
reduce inequities. Awareness of what etiologies account for
disparities is necessary to mitigating them.
Census data have consistently shown that higher levels
of poverty and lower rates of insurance exist inHispanic and
African American communities when compared with Cau-
casian communities.31 Our study showed that insurance
was not predictive of intervention in our patient cohorts.
JOURNAL OF VASCULAR SURGERY
December 20091346 Amaranto et alHowever, we did not record different levels of coverage,
including which patients may be underinsured. Unfortu-
nately, underinsurance rates are difficult to measure, but
they nonetheless serve as a significant barrier to healthcare
access.33,34 Patients with less coverage face higher costs for
surgery and thus they are less likely to opt for interven-
tion.29 Therefore, a lack of insurance and underinsurance
both contribute to treatment disparities.
Patients’ mistrust of healthcare and misunderstandings
of disease severity can contribute to their disinclination to
undergo surgery. Minorities and the poor often live in
urban areas where disadvantages to accessing healthcare are
greatest.29 Urban hospitals in these communities are over-
worked and are generally less able to provide adequate
treatment for severely diseased patients.29,30,32 These set-
tings can lead to hastening of disease progression, nega-
tively affect patient attitudes, and reduce patient under-
standing of the consequences of delayed intervention.
The physician can have a positive or negative effect on
treatment disparities. We recorded which patients had pre-
operative visits to our outpatient clinic in order to deter-
mine if consultation with one of our institution’s vascular
surgeons influenced the surgeon’s decision to intervene.
Patients who were seen in clinic but did not undergo
intervention may have declined an option offered by their
physician. Unfortunately, we were unable to determine
who may have declined an offer for intervention. For the
PAD cohort, being evaluated preoperatively in our clinic
was not significantly associated with intervention. For the
carotid artery disease cohort, in which race was identified as
an independent predictor of intervention, a preoperative
clinic evaluation was an independent predictor of interven-
tion. Therefore, the barriers between minorities and inter-
vention may be reinforced by not referring patients to the
appropriate specialist. In sum, physicians may be able to
reduce disparities by encouraging minority patients to un-
derstand all the options available to them.
Recent efforts that aim to increase the presence of
minorities in healthcare professions offer a promising op-
portunity to encourage members of disadvantaged com-
munities to take advantage of better treatments. Placing
members of minority communities in positions to provide
healthcare establishes a trust between provider and patient
that has been largely absent from the minority medical
experience in America. These efforts can also work to
successfully reduce or eliminate treatment disparities.
As with any retrospective study, there were several
limitations to this research. This was a single-institution
study, and it may not reflect national trends. For PAD, we
were not able to record the extent to which symptoms
affected patients. The severity of disease was determined by
the ABI, which cannot solely quantify the disruption and
inconvenience that a patient experiences from claudication
due to PAD. Furthermore, the medical records we re-
viewed relied on patients’ reporting of their surgical and
medical histories and may not have been completely accu-
rate. Also complicating the analysis of our study was the
sample size. While our PAD cohort was large (n  592),the carotid artery disease cohort was smaller (n 253). We
observed significant trends in treatment disparity among
gender for this cohort, yet it did not reach statistical signif-
icance. In particular, there was a seemingly large but insig-
nificant difference in intervention rates between men and
women with symptomatic carotid artery disease. A greater
sample size may have clarified whether or not gender con-
tributed to the treatment algorithm. It is also possible that
some of the patients with disease identified at our hospital
sought treatment at other institutions. There were 410 of
592 PAD patients and 93 of 253 patients with carotid
artery disease who had only one vascular laboratory study
and no intervention. These patients may have declined to
be treated, were lost to follow-up, or may have sought
treatment at outside institutions that we were unable to
record. Lastly, we were unable to determine the number of
patients lost to follow-up due to the retrospective nature of
this study.
In conclusion, our data revealed no evidence of a
gender disparity in the treatment of PAD or carotid artery
disease. However, our data did identify the presence of a
statistically significant difference in the treatment of Cau-
casians versus non-Caucasians for carotid artery disease and
critical limb ischemia. When compared with data from 15
years ago, these findings are encouraging as they show a
more equitable treatment of men and women. However,
the findings are alarming because they reveal an unexpected
racial disparity. Physicians can encourage patients with
severe disease to seek treatment, especially minority pa-
tients who are faced with negative external factors like
underinsurance or mistrust of healthcare systems. Thus,
staying aware of disparities and the issues facing minority
populations may work to improve equity.
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